Actively Recruiting
Interest of Adaptive Stereotactic Radiotherapy in Localized Prostate Cancer
Led by Clinique Sainte Clotilde · Updated on 2026-01-15
100
Participants Needed
1
Research Sites
8 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating whether adaptive stereotactic body radiotherapy (SBRT) offers advantages over non-adaptive SBRT for treating localized prostate cancer in men aged 60 years and older. The study focuses on how anatomical changes, such as bladder filling and rectal volume, might affect radiation dosing. It also examines the overall dose delivered to nearby organs, patient quality of life over two years, and survival without cancer recurrence. Participants receive five low-dose, non-contrast CT scans taken immediately before each SBRT session to check for anatomical changes that could impact treatment. These scans help determine if recalculating the radiation dose is necessary to better target the prostate and protect surrounding organs. The study tracks these measurements across all five treatment sessions within approximately ten days. Throughout the study, patients report on their quality of life and urinary symptoms before treatment and at several points up to 24 months after radiotherapy. Researchers monitor survival and cancer recurrence at multiple intervals within the two-year follow-up. Participants are carefully informed and provide consent, with ongoing evaluations to assess treatment impact and safety over time.
CONDITIONS
Brief Title
Adaptive Stereotactic Radiotherapy for Localized Prostate Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male aged 60 years or older
- Localized prostate cancer of low or intermediate risk (T1-T2)
- Gleason score 6-7
- PSA level less than 15 ng/mL
- No evidence of metastatic disease
- Radiotherapy indicated for prostate cancer
- Affiliated with or benefiting from French social security
- French-speaking patient
- Patient informed and signed written consent
You will not qualify if you...
- Unable to read, write, or understand French
- Vulnerable patient as defined by French Public Health Code
- Adult under guardianship, curatorship, or legal protection
- Unable to personally provide informed consent
- Currently enrolled in another interventional study that may interfere
- History of urological or digestive surgery affecting outcomes
- Refusal to sign written informed consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 10 days
Participants undergo five low-dose CT scans immediately before each stereotactic body radiotherapy (SBRT) session to assess anatomical variations affecting treatment planning.
5 visits (in-person, before each SBRT session)
Duration - 24 months post-radiotherapy
Participants are monitored for changes in quality of life, urinary symptoms, survival, and recurrence-free survival after radiotherapy.
Visits at baseline, 1, 3, 6, 12, 18, and 24 months post-radiotherapy
Trial Site Locations
Total: 1 location
1
Clinique Sainte Clotilde
Saint-Denis, Reunion, 97404
Actively Recruiting
Research Team
M
MANON Leprince, Clinical Research Associate
M
Mickael Begue, Principal Investigator
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here